Half E - Search Results

1

HER-2 receptor expression, localization, and activation in colorectal cancer cell lines and human tumors.

Half E, Broaddus R, Danenberg KD, Danenberg PV, Ayers GD, Sinicrope FA. Half E, et al. Int J Cancer. 2004 Feb 10;108(4):540-8. doi: 10.1002/ijc.11599. Int J Cancer. 2004. PMID: 14696118

2

Cyclooxygenase-2 expression in human breast cancers and adjacent ductal carcinoma in situ.

Half E, Tang XM, Gwyn K, Sahin A, Wathen K, Sinicrope FA. Half E, et al. Cancer Res. 2002 Mar 15;62(6):1676-81. Cancer Res. 2002. PMID: 11912139

3

Cyclooxygenase-2 overexpression inhibits death receptor 5 expression and confers resistance to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human colon cancer cells.

Tang X, Sun YJ, Half E, Kuo MT, Sinicrope F. Tang X, et al. Among authors: half e. Cancer Res. 2002 Sep 1;62(17):4903-8. Cancer Res. 2002. PMID: 12208739

4

Cyclooxygenase-2 overexpression reduces apoptotic susceptibility by inhibiting the cytochrome c-dependent apoptotic pathway in human colon cancer cells.

Sun Y, Tang XM, Half E, Kuo MT, Sinicrope FA. Sun Y, et al. Among authors: half e. Cancer Res. 2002 Nov 1;62(21):6323-8. Cancer Res. 2002. PMID: 12414664

5

Cell proliferation and apoptotic indices predict adenoma regression in a placebo-controlled trial of celecoxib in familial adenomatous polyposis patients.

Sinicrope FA, Half E, Morris JS, Lynch PM, Morrow JD, Levin B, Hawk ET, Cohen DS, Ayers GD, Stephens LC; Familial Adenomatous Polyposis Study Group. Sinicrope FA, et al. Among authors: half e. Cancer Epidemiol Biomarkers Prev. 2004 Jun;13(6):920-7. Cancer Epidemiol Biomarkers Prev. 2004. PMID: 15184247 Clinical Trial.

6

Anti-EGFR and ErbB-2 antibodies attenuate cyclooxygenase-2 expression and cooperatively inhibit survival of human colon cancer cells.

Half E, Sun Y, Sinicrope FA. Half E, et al. Cancer Lett. 2007 Jun 28;251(2):237-46. doi: 10.1016/j.canlet.2006.11.020. Epub 2006 Dec 26. Cancer Lett. 2007. PMID: 17189670

7

The safety and efficacy of celecoxib in children with familial adenomatous polyposis.

Lynch PM, Ayers GD, Hawk E, Richmond E, Eagle C, Woloj M, Church J, Hasson H, Patterson S, Half E, Burke CA. Lynch PM, et al. Among authors: half e. Am J Gastroenterol. 2010 Jun;105(6):1437-43. doi: 10.1038/ajg.2009.758. Epub 2010 Mar 16. Am J Gastroenterol. 2010. PMID: 20234350 Clinical Trial.

8

Evaluation of difluoromethylornithine for the chemoprevention of Barrett's esophagus and mucosal dysplasia.

Sinicrope FA, Broaddus R, Joshi N, Gerner E, Half E, Kirsch I, Lewin J, Morlan B, Hong WK. Sinicrope FA, et al. Among authors: half e. Cancer Prev Res (Phila). 2011 Jun;4(6):829-39. doi: 10.1158/1940-6207.CAPR-10-0243. Cancer Prev Res (Phila). 2011. PMID: 21636549

9

An international randomised trial of celecoxib versus celecoxib plus difluoromethylornithine in patients with familial adenomatous polyposis.

Lynch PM, Burke CA, Phillips R, Morris JS, Slack R, Wang X, Liu J, Patterson S, Sinicrope FA, Rodriguez-Bigas MA, Half E, Bulow S, Latchford A, Clark S, Ross WA, Malone B, Hasson H, Richmond E, Hawk E. Lynch PM, et al. Among authors: half e. Gut. 2016 Feb;65(2):286-95. doi: 10.1136/gutjnl-2014-307235. Epub 2015 Mar 19. Gut. 2016. PMID: 25792707 Free article. Clinical Trial.

10

Treatment of Hereditary Colorectal Cancer Syndromes.

Half EE, Bresalier RS. Half EE, et al. Curr Treat Options Gastroenterol. 2004 Jun;7(3):213-224. doi: 10.1007/s11938-004-0042-0. Curr Treat Options Gastroenterol. 2004. PMID: 15149583

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

65 results

Search Page

Filters